CSI Market
Sign In | Register

Neubase Therapeutics inc (NBSE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NBSE Annual Cash Flow →
Looking at cash flow data from Neubase Therapeutics inc through Sep 30 2022 provides insight into Sep 30 2023's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-9.36
Depreciation & amortization0.51
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets to be Disposed of0.86
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.06
Share-based Compensation0.27
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-2.24
Fair Value Of Warrants Issued For Services-
Gain Loss On Extinguishment Of Debt-
Increase Decrease In Prepaid Expenses And Deposits-
Common Stock And Warrants Issued In Advance Of Services-
Notes Issued-
Conversion Of Stock Amount Converted-
Stock Issued-
Warrants Issued For Services-
Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense-
Research And Development Expense License Acquired-
Research And Development Expense License-
Operating Lease Right Of Use Asset Amortization Expense0.35
Increase Decrease In Operating Lease Liability-0.35
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.11
Increase (Decrease) in Accrued Liabilities-0.77
Increase (Decrease) in Security Deposits0.15
Increase (Decrease) in Prepaid Expense and Other Assets0.23
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.31
Discontinued operations0.00
Net Cash flow from Operating Activities-9.09
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.01
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payment Of Transaction Cost To Acquire Intangible Assets-
Payment Of Transaction Cost To Acquire License Of Intangible Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Convertible Notes-
Payment Of Financing Insurance-
Proceeds From Issuance Of Common Stock For Services-
Proceeds From Issuance Of Common Stock In Pre Acquisition Financing Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Warrants Net4.36
Finance Lease Principal Payments-0.08
Payment In Lieu Of Fractional Shares From Reverse Stock Split0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.28
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-9.10
Total Cash Flow-4.82
4 historic quarters locked

Sign in to unlock the full Neubase Therapeutics inc cash flow history.

Sign In Create Free Account

About Neubase Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-018577

Figures are derived from filed reports and may be restated. Historical data is subject to revision.